Moreover, the platelet‐derived growth factor receptor (PDGFR) inhibitors sunitinib and ponatinib significantly suppress the proliferation and metastasis of triple‐negative breast cancer cell lines.[9] In malignant melanoma, PDGFC dimers promote tumor growth in a paracrine manner by recruiting and activating cancer‐associated fibroblasts (CAFs).[10] These studies have indicated that PDGFC may be involved in the malignant progression of various tumors, but the specific cancer‐promoting mechanisms are quite different. The gene discussed is PDGFC; the disease is melanoma.